http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results
-
Marinus Pharmaceuticals Names Dr. Rolando GutÃerrez-Esteinou as VP of Clinical Development and Pharmacovigilance
-
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Marinus Pharma (MRNS) Reports Complete Enrollment for Magnolia Postpartum Depression Study
-
Marinus Completes Enrollment in its Magnolia Postpartum Depression Study
-
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Marinus Pharma (MRNS) Announces Scott Braunstein MD to Board
-
Marinus Appoints Scott Braunstein, MD to its Board of Directors
-
Marinus Pharmaceuticals to Present at the Baird Healthcare Conference
-
Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference
-
Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results
-
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index
-
Marinus Pharma (MRNS) Commences Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder
-
Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder
-
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
-
Marinus Pharmaceuticals to Present at the UBS Global Healthcare Conference
-
Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results
-
Marinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference
-
Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results
-
Marinus Pharmaceuticals to Attend Upcoming Investor Conferences
-
Marinus Pharmaceuticals Added to NASDAQ Biotechnology Index
-
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results
-
Marinus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Marinus Pharma (MRNS) Reports Successful Clinical Trial Results from Phase 2 Study in Patients with CDKL5 Disorder
-
Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone
-
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2017 Financial Results
-
Marinus Pharma (MRNS) Says FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder
-
FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder
-
Marinus Pharma (MRNS) Launches Ganaxolone Clinical Program in Patients with PPD
-
Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression
-
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2017 Financial Results
-
Marinus Pharma (MRNS) to Present Ganaxolone DATA at AAN
-
Marinus to present Ganaxolone DATA at American academy of neurology annual meeting
-
Ligand Pharma (LGND) Announces Commercial License and Supply Agreements with Marinus Pharmaceuticals (MRNS) for Captisol-Enabled Ganaxolone
-
Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone

